Molecular modelling of CYP2B6 based on homology with the CYP2C5 crystal structure: Analysis of enzyme-substrate interactions

Drug Metabolism and Drug Interactions

Volumn 19, Issue 2, 2002, Pages 115-135

  Lewis, David F V ^a   Lake, Brian G ^b   Dickins, Maurice ^c   Goldfarb, Peter S ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b BIBRA INTERNATIONAL   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

CYP2 structural template; Cytochrome P450; Modelling; Xenobiotic metabolism and activation

Indexed keywords

3 CYANO 7 ETHOXYCOUMARIN; 3,5 DIMETHYL 2 (3 PYRIDYL) 4 THIAZOLIDINONE; 4 CHLOROMETHYL 7 ETHOXYCOUMARIN; 4 TRIFLUOROMETHYL 7 ETHOXYCOUMARIN; 7 ETHOXYCOUMARIN; AMFEBUTAMONE; BENZPHETAMINE; BENZYLOXYRESORUFIN; COUMARIN DERIVATIVE; CYTOCHROME P450 101; CYTOCHROME P450 102; CYTOCHROME P450 2B6; CYTOCHROME P450 2C5; DIAZEPAM; ETHOXYCOUMARIN; MEPHENYTOIN; METHOXYCHLOR; PHENAZONE; PICLAMILAST; PNU 249173; RESORUFIN DERIVATIVE; TESTOSTERONE; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME ANALYSIS; ENZYME BINDING; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; HYDROGEN BOND; LIPOPHILICITY; MOLECULAR MODEL; PARTITION COEFFICIENT; PROTEIN FAMILY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SITE DIRECTED MUTAGENESIS; STRUCTURE ANALYSIS;

EID: 0038076447     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2002.19.2.115     Document Type: Article

References (41)

1. Lewis DFV. Cytochromes P450: Structure, Function and Mechanism. London: Taylor & Francis, 1996.
2. Lewis DFV. Guide to Cytochrome P450 Structure and Function. London: Taylor & Francis, 2001.
3. Guengerich FP. Cytochrome P450. In: loannides C, ed. Enzyme Systems that Metabolize Drugs and other Xenobiotics. New York: Wiley, 2002; 33-65.
4. Rendic S, DiCarlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab Rev 1997; 29: 413-580.
5. Ingelman-Sundberg M. Implications of polymorphic cytochrome P450-dependent drug metabolism for drug development. Drug Metab Dispos 2001; 29: 570-573.
6. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharm Scie 1999; 20: 342-349.
7. Evans WE, Relling MV. Phannacogenomics: translating functional genomics into rational therapies. Science 1999; 286: 487-491.
8. Ekins S, Wrighton SA. The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev 1999; 31: 719-754.
9. Rae JM, Soukhova NV, Flockhart DA, Desta Z. Triethyl-enethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos 2002; 30: 525-530.
10. Wang Q, Halpert JR. Combined three-dimensional quantitative structure-activity relationship analysis of cytochrome P450 2B6 substrates and protein homology modeling. Drug Metab Dispos 2002; 30: 86-95.
11. Williams PA, Cosine J, Sridhar V, Johnson EF, McRee DE. Mammalian cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell 2000; 5: 121-131.
12. Lewis DFV. Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure. Xenobiotica 2002; 32: 305-323.
13. Lewis DFV, Lake BF, Dickins M, Eddershaw PJ, Tarbit MH, Goldfarb PS. Molecular modelling of CYP2B6, the human CYP2B isoform, by homology with the substrate-bound CYP102 crystal structure: evaluation of CYP2B6, CYP2B1 and CYP2B4 substrate characteristics. Xenobiotica 1999; 29: 361-393.
14. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002; 34: 83-448.
15. Lewis DFV. The CYP2 family: models, mutants and interactions. Xenobiotica 1998; 28: 617-661.
16. Domanski TL, Halpert JR. Analysis of mammalian cytochrome P450 structure and function by site-directed inutagenesis. Curr Drug Metab 2001; 2: 117-137.
17. Lewis DFV. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics. Biochem Phannacol 2000; 60: 293-306.
18. Lewis DFV. Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles. Toxicology 2000; 144: 197-203.
19. Ekins S, Bravi G, Ring BJ, Gillespie TA, Gillespie JS, VandenBranden M, Wrighton SA, Wikel JH. Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. J Phannacol Exp Ther 1999; 288: 21-29.
20. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 1992; 267: 83-90.
21. Lewis DFV, Eddershaw PJ, Dickins M, Tarbit MH, Goldfarb PS. Structural determinants of P450 substrate specificity, binding affinity and catalytic rate. Chem-Biol Interact 1998; 115: 175-199.
22. Lewis DFV, Modi S, Dickins M. Structure-activity relationships for human cytochrome P450 substrates and inhibitors. Drug Metab Rev 2002; 34: 69-82.
23. Lewis DFV. Baseline lipophilicity relationships in human cytochromes P450 associated with drug metabolism. Drug Metab Rev 2003; 35: 1-18.
24. Heyn H, White RC, Stevens JC. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metab Dispos 1996; 24: 948-954.
25. Dehal SS, Kupfer D. Metabolism of the proestrogenic pesticide methoxychlor by hepatic P450 monooxygenases in rats and humans. Drug Metab Dispos 1994; 22: 937-946.
26. Stevens J, Hauer M, Beck J, Voorman R. Further characterization of human liver CYP2B6 expression and catalytic function. Drug Metab Rev 2000; 32: 218.
27. Yong TJ, Shou M, Korzekwa KR, Gonzalez FJ, Gelboin HV, Yang SK. Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam. Biochem Pharmacol 1998; 55: 889-896.
28. Kobayashi Y, Strobel SM, Hopkins NE, Alworth WL, Halpert JR. Catalytic properties of an expressed cytochrome P450 2B1 from a Wistar-Kyoto rat liver cDNA library. Drug Metab Dispos 1998; 26: 1026-1030.
29. Szklarz GD, He YQ, Kedzie KM, Halpert JR, Burnett VL. Elucidation of amino acid residues critical for unique activities of rabbit P4502B5 using hybrid enzymes and reciprocal site-directed mutagenesis with rabbit cytochrome P450 2B4. Arch Biochem Biophys 1996; 327: 308-318.
30. Hasler JA, Harlow GR, Szklarz GD, John GH, Kedzie KM, Burnett VL, He YA, Kaminsky LS, Halpert JR. Site-directed mutagenesis of putative substrate recognition sites in cytochrome P450 2B11: importance of amino acid residues 114, 290 and 363 for substrate specificity. Mol Pharmacol 1994; 46: 338-345.
31. He Y, Luo Z, Klekotka PA, Burnett VL, Halpert JR. Structural determinants of cytochrome P450 2B1 specificity: evidence of five substrate recognition sites. Biochemistry 1994; 33: 4419-4424.
32. Szklarz GD, He YA, Halpert JR. Site-directed mutagenesis as a tool for molecular modelling of cytochrome P4502B1. Biochemistry 1995; 34: 14312-14322.
33. Harlow GR, Halpert JR. Mutagenesis study of Asp-290 in cytochrome P4502B11 using a fusion protein with rat NADPH-cytochrome P450 reductase. Arch Biochem Biophys 1996; 326: 85-92.
34. Harlow GR, He YA, Halpert JR. Functional interaction between amino acid residues 242 and 290 in cytochromes P450 2B1 and 2B11. Biochim Biophys Acta 1997; 1338: 259-266.
35. He YQ, He YA, Halpert JR. Escherichia coli expression of site-directed mutants of cytochrome P450 2B1 from 6 substrate recognition sites: substrate specificity and inhibitor selectivity studies. Chem Res Toxicol 1995; 8: 574-579.
36. Vaz ADN, Pernecky SJ, Raner GM, Coon MJ. Peroxo-iron and oxenoid-iron species as alternative oxygenating agents in cytochrome P450-catalyzed reactions: switching by threonine-302 to alanine mutagenesis of cytochrome P450 2B4. Proc Natl Acad Sci USA 1996; 93: 4644-4648.
37. Born SL, John GH, Harlow GR, Halpert JR. Characterization of the progesterone 21-hydroxylase activity of canine cytochrome P450 PBD-2/P450 2B11 through reconstitution, heterologous expression and site-directed mutagenesis. Drug Metab Dispos 1995; 23: 702-707.
38. Halpert JR, He Y. Engineering of cytochrome P450 2B1 specificity. J Biol Chem 1993; 268: 4453-4457.
39. Halpert JR. Structural basis of selective cytochrome P450 inhibitor. Annu Rev Pharmacol Toxicol 1995; 35: 29-53.
40. Waller SC, He YA, Harlow GR, He YQ, Mash EA, Halpert JR. 2,2′,3,3′,6,6′-Hexachlorobiphenyl hydroxylation by active site mutants of cytochrome P450 2B1 and 2B11. Chem Res Toxicol 1999; 12: 690-699.
41. Domanski TL, He Y-Q, Scott EE, Wang Q, Halpert JR. The role of cytochrome P450 2B1 substrate recognition site residues 115, 294, 297, 298 and 362 in the oxidation of steroids and 7-alkoxycoumarins. Arch Biochem Biophys 2001; 394: 21-28.